Skip to main content

Advertisement

SpringerLink
Log in

Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres

  • Original Paper
  • Published:
The European Journal of Health Economics Aims and scope Submit manuscript

Abstract

Background

Despite the widespread availability of biological drugs in psoriasis, there is a shortage of disease burden studies.

Objectives

To assess the cost-of-illness and quality of life of patients with moderate to severe psoriasis in Hungary.

Methods

Consecutive patients with Psoriasis Area and Severity Index (PASI) > 10 and Dermatology Life Quality Index (DLQI) > 10, or treated with traditional systemic (TST) or biological systemic treatment (BST) were included. Demographic data, clinical characteristics, psoriasis related medication, health care utilizations and employment status in the previous 12 months were recorded. Costing was performed from the societal perspective applying the human capital approach. Quality of life was assessed using DLQI and EQ-5D measures.

Results

Two-hundred patients were involved (females 32 %) with a mean age of 51 (SD 13) years, 103 (52 %) patients were on BST. Mean PASI, DLQI and EQ-5D scores were 8 (SD 10), 6 (SD 7) and 0.69 (SD 0.3), respectively. The mean total cost was €9,254/patient/year (SD 8,502) with direct costs accounting for 86 %. The main cost driver was BST (mean €7,339/patient/year). Total costs differed significantly across treatment subgroups, mean (SD): no systemic therapy €2,186 (4,165), TST €2,388 (4,106) and BST €15,790 (6,016) (p < 0,001). Patients with BST had better PASI and DLQI scores (p < 0.01) than the other two subgroups.

Conclusions

Patients with biological treatment have a significantly better quality of life and higher total costs than patients with or without traditional systemic treatment. Our study is the largest in Europe and the first in the CEE region that provides cost-of-illness data in psoriasis involving patients with BST.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Parisi, R., Symmons, D.P., Griffiths, C.E., Ashcroft, D.M.: Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J. Invest. Dermatol. 133(2), 377–385 (2013). doi:10.1038/jid.2012.339

    Article  CAS  PubMed  Google Scholar 

  2. Menter, A., Korman, N.J., Elmets, C.A., Feldman, S.R., Gelfand, J.M., Gordon, K.B., Gottlieb, A., Koo, J.Y., Lebwohl, M., Lim, H.W., Van Voorhees, A.S., Beutner, K.R., Bhushan, R.: Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J. Am. Acad. Dermatol. 60(4), 643–659 (2009). doi:10.1016/j.jaad.2008.12.032

    Article  PubMed  Google Scholar 

  3. EMA, C.f.M.P.f.H.U.: Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003329.pdf (2004)

  4. Menter, A., Korman, N.J., Elmets, C.A., Feldman, S.R., Gelfand, J.M., Gordon, K.B., Gottlieb, A., Koo, J.Y., Lebwohl, M., Leonardi, C.L., Lim, H.W., Van Voorhees, A.S., Beutner, K.R., Ryan, C., Bhushan, R.: Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J. Am. Acad. Dermatol. 65(1), 137–174 (2011). doi:10.1016/j.jaad.2010.11.055

    Article  PubMed  Google Scholar 

  5. Richard, M.A., Barnetche, T., Horreau, C., Brenaut, E., Pouplard, C., Aractingi, S., Aubin, F., Cribier, B., Joly, P., Jullien, D., Le Maitre, M., Misery, L., Ortonne, J.P., Paul, C.: Psoriasis, cardiovascular events, cancer risk and alcohol use: evidence-based recommendations based on systematic review and expert opinion. J. Eur. Acad. Dermatol. Venereol. 27(Suppl 3), 2–11 (2013). doi:10.1111/jdv.12162

    Article  PubMed  Google Scholar 

  6. Ogdie, A., Haynes, K., Troxel, A.B., Love, T.J., Hennessy, S., Choi, H., Gelfand, J.M.: Risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study. Ann. Rheum. Dis. 73(1), 149–153 (2014). doi:10.1136/annrheumdis-2012-202424

    Article  PubMed  Google Scholar 

  7. Dhir, V., Aggarwal, A.: Psoriatic arthritis: a critical review. Clin. Rev. Allergy Immunol. 44(2), 141–148 (2013). doi:10.1007/s12016-012-8302-6

    Article  PubMed  Google Scholar 

  8. Radtke, M.A., Augustin, M.: Economic considerations in psoriasis management. Clin. Dermatol. 26(5), 424–431 (2008). doi:10.1016/j.clindermatol.2007.10.024

    Article  PubMed  Google Scholar 

  9. Raho, G., Koleva, D.M., Garattini, L., Naldi, L.: The burden of moderate to severe psoriasis: an overview. Pharmacoeconomics 30(11), 1005–1013 (2012). doi:10.2165/11591580-000000000-00000

    Article  PubMed  Google Scholar 

  10. Herédi, E., Rencz, F., Balogh, O., Gulácsi, L., Herszényi, K., Holló, P., Jókai, H., Kárpáti, S., Péntek, M., Remenyik, É., Szegedi, A., Brodszky, V.: Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary. The European Journal of Health Economics (in press) (2014)

  11. Finlay, A.Y.: Current severe psoriasis and the rule of tens. Br. J. Dermatol. 152(5), 861–867 (2005). doi:10.1111/j.1365-2133.2005.06502.x

    Article  CAS  PubMed  Google Scholar 

  12. Reilly, M.C., Zbrozek, A.S., Dukes, E.M.: The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 4(5), 353–365 (1993)

    Article  CAS  PubMed  Google Scholar 

  13. Finlay, A.Y., Khan, G.K.: Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin. Exp. Dermatol. 19(3), 210–216 (1994)

    Article  CAS  PubMed  Google Scholar 

  14. Kind, P., Dolan, P., Gudex, C., Williams, A.: Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 316(7133), 736–741 (1998)

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Pathirana, D., Ormerod, A.D., Saiag, P., Smith, C., Spuls, P.I., Nast, A., Barker, J., Bos, J.D., Burmester, G.R., Chimenti, S., Dubertret, L., Eberlein, B., Erdmann, R., Ferguson, J., Girolomoni, G., Gisondi, P., Giunta, A., Griffiths, C., Honigsmann, H., Hussain, M., Jobling, R., Karvonen, S.L., Kemeny, L., Kopp, I., Leonardi, C., Maccarone, M., Menter, A., Mrowietz, U., Naldi, L., Nijsten, T., Ortonne, J.P., Orzechowski, H.D., Rantanen, T., Reich, K., Reytan, N., Richards, H., Thio, H.B., van de Kerkhof, P., Rzany, B.: European S3-guidelines on the systemic treatment of psoriasis vulgaris. J. Eur. Acad. Dermatol. Venereol. 23(Suppl 2), 1–70 (2009). doi:10.1111/j.1468-3083.2009.03389.x

    Article  PubMed  Google Scholar 

  16. Hungarian Central Statistical Office: Gross wages and salaries (2001-2012). http://www.ksh.hu/docs/hun/eurostat_tablak/tabl/tec00014.html (2012). Accessed 1 September 2013

  17. National Health Insurance Fund Administration: Official list of drugs (2012). Accessed 1 Sept 2013

  18. DRG: Disease Related Groups. http://www.gyogyinfok.hu/magyar/hbcs_konyv.html (2011). Accessed 1 Sept 2013

  19. Centre for Budapest Transport. http://www.bkk.hu/en/prices/ (2012). Accessed 1 Sept 2013

  20. Debrecen Transport Services Closed Corporation. http://www.dkv.hu/en/fares (2012). Accessed 1 Sept 2013

  21. Ministry of Health—National Health Insurance Fund’s prospectus of the monthly payment of financing of curative and preventing care. In. (2012)

  22. Koopmanschap, M.A., Rutten, F.F.: A practical guide for calculating indirect costs of disease. Pharmacoeconomics 10(5), 460–466 (1996)

    Article  CAS  PubMed  Google Scholar 

  23. Koopmanschap, M.A., Rutten, F.F., van Ineveld, B.M., van Roijen, L.: The friction cost method for measuring indirect costs of disease. J. Health Econ. 14(2), 171–189 (1995)

    Article  CAS  PubMed  Google Scholar 

  24. Laki, J., Monok, G., Palosi, M., Gajdacsi, J.Z.: Economical aspect of biological therapy in inflammatory conditions in Hungary. Expert Opin. Biol. Ther. 13(3), 327–337 (2013). doi:10.1517/14712598.2013.735654

    Article  PubMed  Google Scholar 

  25. Szende, A., Nemeth, R.: Health-related quality of life of the Hungarian population. Orv. Hetil. 144(34), 1667–1674 (2003)

    PubMed  Google Scholar 

  26. Ciocon, D.H., Horn, E.J., Kimball, A.B.: Quality of life and treatment satisfaction among patients with psoriasis and psoriatic arthritis and patients with psoriasis only: results of the 2005 Spring US National Psoriasis Foundation Survey. Am. J. Clin. Dermatol. 9(2), 111–117 (2008)

    Article  PubMed  Google Scholar 

  27. Brodszky, V., Balint, P., Geher, P., Hodinka, L., Horvath, G., Koo, E., Pentek, M., Polgar, A., Sesztak, M., Szanto, S., Ujfalussy, I., Gulacsi, L.: Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment. Rheumatol. Int. 30(2), 199–205 (2009). doi:10.1007/s00296-009-0936-1

    Article  PubMed  Google Scholar 

  28. Fonia, A., Jackson, K., Lereun, C., Grant, D.M., Barker, J.N., Smith, C.H.: A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis. Br. J. Dermatol. 163(4), 807–816 (2010). doi:10.1111/j.1365-2133.2010.09944.x

    Article  CAS  PubMed  Google Scholar 

  29. Driessen, R.J., Bisschops, L.A., Adang, E.M., Evers, A.W., Van De Kerkhof, P.C., De Jong, E.M.: The economic impact of high-need psoriasis in daily clinical practice before and after the introduction of biologics. Br. J. Dermatol. 162(6), 1324–1329 (2010). doi:10.1111/j.1365-2133.2010.09693.x

    Article  CAS  PubMed  Google Scholar 

  30. Kimball, A.B., Guerin, A., Tsaneva, M., Yu, A.P., Wu, E.Q., Gupta, S.R., Bao, Y., Mulani, P.M.: Economic burden of comorbidities in patients with psoriasis is substantial. J. Eur. Acad. Dermatol. Venereol. 25(2), 157–163 (2011). doi:10.1111/j.1468-3083.2010.03730.x

    Article  CAS  PubMed  Google Scholar 

  31. Gleason, P.P., Alexander, G.C., Starner, C.I., Ritter, S.T., Van Houten, H.K., Gunderson, B.W., Shah, N.D.: Health plan utilization and costs of specialty drugs within 4 chronic conditions. J. Manag. Care Pharm. 19(7), 542–548 (2013)

    PubMed  Google Scholar 

  32. Le Moigne, M., Sommet, A., Lapeyre-Mestre, M., Bourrel, R., Molinier, L., Paul, C., Montastruc, J.L.: Healthcare cost impact of biological drugs compared with traditional systemic treatments in psoriasis: a cohort analysis in the French insurance database. J. Eur. Acad. Dermatol. Venereol. (2013). doi:10.1111/jdv.12318

    PubMed  Google Scholar 

  33. Levy, A.R., Davie, A.M., Brazier, N.C., Jivraj, F., Albrecht, L.E., Gratton, D., Lynde, C.W.: Economic burden of moderate to severe plaque psoriasis in Canada. Int. J. Dermatol. 51(12), 1432–1440 (2012). doi:10.1111/j.1365-4632.2011.05359.x

    Article  PubMed  Google Scholar 

  34. Ghatnekar, O., Ljungberg, A., Wirestrand, L.E., Svensson, A.: Costs and quality of life for psoriatic patients at different degrees of severity in southern Sweden—a cross-sectional study. Eur. J. Dermatol. 22(2), 238–245 (2012). doi:10.1684/ejd.2011.1635

    PubMed  Google Scholar 

  35. Tang, M.M., Chang, C.C., Chan, L.C., Heng, A.: Quality of life and cost of illness in patients with psoriasis in Malaysia: a multicenter study. Int. J. Dermatol. 52(3), 314–322 (2013). doi:10.1111/j.1365-4632.2011.05340.x

    Article  PubMed  Google Scholar 

  36. Steinke, S.I., Peitsch, W.K., Ludwig, A., Goebeler, M.: Cost-of-illness in psoriasis: comparing inpatient and outpatient therapy. PLoS ONE 8(10), e78152 (2013). doi:10.1371/journal.pone.0078152PONE-D-13-23199

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

The authors are grateful to patients participating in the survey. Proofreading of the manuscript was supported by the TÁMOP 4.2.2./B-10/1-2010-0023 project.

Author information

Authors and Affiliations

  1. Department of Health Economics, Corvinus University of Budapest, Fővám tér 8, 1093, Budapest, Hungary

    Orsolya Balogh, Valentin Brodszky, László Gulácsi & Petra Baji

  2. Department of Dermatology and Dermatological Allergology, University of Debrecen, Nagyerdei krt. 98., 4032, Debrecen, Hungary

    Emese Herédi, Éva Remenyik & Andrea Szegedi

  3. Department of Dermatovenereology and Oncodermatology, Semmelweis University, Mária u. 41, 1085, Budapest, Hungary

    Krisztina Herszényi, Hajnalka Jókai, Sarolta Kárpáti & Péter Holló

Authors
  1. Orsolya Balogh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Valentin Brodszky
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. László Gulácsi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Emese Herédi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Krisztina Herszényi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hajnalka Jókai
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sarolta Kárpáti
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Petra Baji
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Éva Remenyik
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Andrea Szegedi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Péter Holló
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to László Gulácsi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Balogh, O., Brodszky, V., Gulácsi, L. et al. Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres. Eur J Health Econ 15 (Suppl 1), 101–109 (2014). https://doi.org/10.1007/s10198-014-0599-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10198-014-0599-z

Keywords

JEL Classification

Search

Navigation